Email this article INNOVATIONS TO TOPICAL THERAPY OF ROSACEA
- Authors: Olisova O.Y.1, Kochergin N.G1, Smirnova E.A.1
-
Affiliations:
- Sechenov First Moscow State Medical University
- Issue: Vol 20, No 5 (2017)
- Pages: 270-274
- Section: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/42718
- DOI: https://doi.org/10.18821/1560-9588-2017-20-5-270-274
- ID: 42718
Cite item
Full Text
Abstract
The main pathogenetic aspects of rosacea, various classifications of dermatosis and the modern clinical classification are presented. The symptoms that differentiate rosacea from other dermatoses are described. Contradictory of modern scientific concepts of different researchers, approaches to etiology, pathogenesis and treatment has been noted. The social significance of rosacea, the importance and possibility of eliminating the symptoms of the disease at early stages, the achievement and prolongation of remission are shown. The main triggers for the manifestation of rosacea, which should be taken into account to achieve the maximum effect in the treatment of the disease, are indicated. The domestic and foreign clinical recommendations on the treatment of the disease are considered in view of the appearance of new external drugs. The results of several studies in the USA and Canada on the efficacy of 1% ivermectin cream and 0.5% brimonidine tartrate gel compared to placebo are shown. The first domestic positive experience of self-study with 1% ivermectin cream (Solantra®) and 0.5% brimonidine tartrate gel (Mirvazo Derm®) is presented. The high efficacy and very good tolerability of this drugs, as well as the absence of any side effects in patients with moderate to severe rosacea are shown.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
O. Yu Olisova
Sechenov First Moscow State Medical UniversityMoscow, 119991, Russian Federation
N. G Kochergin
Sechenov First Moscow State Medical UniversityMoscow, 119991, Russian Federation
Elena A. Smirnova
Sechenov First Moscow State Medical University
Email: doctor.e.smirnova@gmail.com
Department of Skin and Venereal Diseases, I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation Moscow, 119991, Russian Federation
References
- Манн М.В., Берк Д.Р., Попкин Д.Л., Бейлисс С.Д. Справочник дерматолога. Практическое руководство. Пер. с англ. М.: Изд. Панфилова; БИНОМ; 2013
- Aziz N., Khachemoune A. A man with changes on nose. J. Am. Acad. Dermatol. 2007; 57(3): 551-4. Available at: http://www.jaad.org/article/S0190-9622(07)00875-4/abstract. (accessed 04.06.2017)
- Прохоренков В.И. Розацеа: современные аспекты этиологии и патогенеза. Клиническая дерматология и венерология. 2015; 1: 4-11.
- Олисова О.Ю., Кочергин Н.Г., Смирнова Е.А. Современная наружная терапия среднетяжёлых форм розацеа. Российский журнал кожных и венерических болезней. 2016; 19(6): 328-34.
- Dirschka T., Micali G., Papadopoulos L., Tan J., Layton A., Moore S. Perceptions on the psychological impact of facial erythema associated with rosacea: results of international survey. Dermatol. Ther. (Heidelb). 2015; 5(2): 117-27.
- Phillips T.J. An update on the safety and efficacy of topical retinoids. Cutis. 2005; 75(2, Suppl): 14-22.
- Музыченко А.П. Розацеа. Учебно-методическое пособие. Минск: БГМУ; 2014.
- Кубанова А.А., Махакова Ю.Б. Розацеа: распространённость, патогенез, особенности клинических проявлений. Вестник дерматологии и венерологии. 2015; (3): 36-45.
- Пинсон И.Я., Верхогляд И.В., Семочкин А.В. Современные представления об этиологии и патогенезе розацеа. Экспериментальная и клиническая дерматокосметология. 2012; 5: 21-4.
- Бутов Ю.С., Скрипкин Ю.К., Иванов О.Л., ред. Дерматовенерология. М.: ГЭОТАР-Медиа; 2013.
- Вольф К., Голдсмит Л.А., Кац С.И., Джилкрест Б.А., Паллер Э.С., Леффель Д.Дж. Дерматология Фицпатрика в клинической практике. Пер. с англ. М.: Изд. Панфилова; БИНОМ; 2012. т.1: 769-74.
- Ахтямов С.Н. Практическая дерматокосметология. Акне, рубцы постакне и акнеформные дерматозы. Руководство для врачей. М.: Медицина; 2010.
- Dahl M.V., Ross A.J., Shlievert P.M. Temperature regulates bacterial protein production: possible role in rosacea. J. Am. Acad. Dermatol. 2004; 50(2): 266-72
- Олисова О.Ю., Кочергин Н.Г., Мураховская Е.К., Кескин Г.М., Олисов А.О., Давидович М. и др. Такролимус в терапии различных дерматозов. Российский журнал кожных и венерических болезней. 2013; 16(5): 57-61.
- Аравийская Е.Р., Самцов А.В. Федеральные клинические рекомендации по ведению больных розацеа. М.; 2013.
- Дел Россо Д. Розацеа кожи: патогенез, клинические проявления, современные рекомендации по тактике ведения пациентов. Вестник дерматологии и венерологии. 2016; 2: 21-31.
- Stein L., Kircik L., Fowler J., Tan J., Draelos Z., Fleischer A., et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J. Drugs Dermatol. 2014; 13(3): 316-23.
- Fowler J., Jackson M., Moore A., Jarratt M., Jones T., Meadows K., et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J. Drugs Dermatol. 2013; 12(6): 650-6.
- Moore A., Kempers S., Murakawa G., Weiss J., Tauscher A., Swinyer L., et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J. Drugs Dermatol. 2014; 13(1): 56-64.
Supplementary files
